Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875726 | 0.83 | GABRA1 (0.43) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL25217287 | 0.79 | KLKB1 (0.36) | — | |
| SCHEMBL17748246 | 0.77 | GABRA1 (0.47) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL2702724 | 0.75 | PTGS1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL19491783 | 0.75 | GABRA1 (0.46) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL30151579 | 0.75 | GABRA1 (0.46) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL29394461 | 0.75 | RXRA (0.47) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL16245769 | 0.75 | TSHR (0.44) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL29671369 | 0.75 | TSHR (0.44) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL19491912 | 0.75 | GABRA1 (0.46) | GABRA1GABRB2PTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102603827-B | Paeoniflorin aromatic ester derivative, preparation method and applications thereof | WEI WEI (CN) | 2014-10-29 | — | — | CN | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| CN-102603827-A | Paeoniflorin aromatic ester derivative, preparation method and applications thereof | WEI WEI | 2012-07-25 | — | — | CN | disclosed |
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-10-21 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | GABRA1 346/4885GABRB2 356/4885PTGS1 128/4885 |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | CXCR2, CXCR1, MMP8 | GABRA1 1367/4885GABRB2 1715/4885PTGS1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.